Total medical devices industry venture financing deals in February 2020 worth $760.99m were announced in the US, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 7.3% over the previous month and a rise of 31.1% when compared with the last 12-month average of $580.48m.
The US held a 75.2% share of the global medical devices industry venture financing deal value that totalled $1.01bn in February 2020.
In terms of deal activity, the US recorded 53 deals during February 2020, marking a decrease of 3.6% over the previous month and a drop of 14.5% over the 12-month average.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe US medical devices industry venture financing deals in February 2020: Top deals
The top five medical devices industry venture financing deals accounted for 59.8% of the overall value during February 2020.
The combined value of the top five medical devices venture financing deals stood at $455m, against the overall value of $760.99m recorded for the month.
The top five medical devices industry deals of February 2020 tracked by GlobalData were:
1) General Catalyst Partners, HBM Healthcare Investments, Khosla Ventures, Lightspeed Management Company and SoftBank Vision Fund’s $165m venture financing of Karius
2) The $125m venture financing of Outset Medical by D1 Capital Partners, Fidelity Management & Research, Partner Fund Management, Perceptive Advisors and T. Rowe Price Group
3) 11.2 Capital, Atomico Ventures, Bessemer Venture Partners, Heuristic Capital Partners Management Co, Insight Partners, Lead Edge Capital Management and Quadrille Capital’s $90m venture financing of Hinge Health
4) The $40m venture financing of Q Bio by Andreessen Horowitz
5) Canaan Partners, Cardinal Health, Casdin Capital, Threshold Ventures, Hive Ventures, Kite Pharma, LifeForce Capital Management, Novartis Pharma and Section 32’s venture financing of Vineti for $35m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
